MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
Metrics to compare | MTST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMTSTPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.5x | −0.6x | |
PEG Ratio | 0.00 | −0.07 | 0.00 | |
Price/Book | 0.0x | 2.9x | 2.6x | |
Price / LTM Sales | 0.0x | 2.8x | 3.2x | |
Upside (Analyst Target) | 0.0% | 29.4% | 47.1% | |
Fair Value Upside | Unlock | 6.6% | 7.1% | Unlock |